Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to $4.3 billion.

  • Gsk's Free Cash Flow rose 163.14% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.6 billion, marking a year-over-year increase of 2413.08%. This contributed to the annual value of $13.6 billion for FY2025, which is 1465.12% up from last year.
  • Gsk's Free Cash Flow amounted to $4.3 billion in Q4 2025, which was up 163.14% from $3.8 billion recorded in Q3 2025.
  • Gsk's 5-year Free Cash Flow high stood at $4.3 billion for Q4 2025, and its period low was $632.1 million during Q1 2023.
  • For the 5-year period, Gsk's Free Cash Flow averaged around $2.8 billion, with its median value being $3.1 billion (2023).
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 31757.14% in 2022, then crashed by 8402.15% in 2023.
  • Quarter analysis of 5 years shows Gsk's Free Cash Flow stood at $3.5 billion in 2021, then dropped by 2.74% to $3.4 billion in 2022, then dropped by 10.37% to $3.0 billion in 2023, then soared by 41.19% to $4.3 billion in 2024, then rose by 1.63% to $4.3 billion in 2025.
  • Its Free Cash Flow stands at $4.3 billion for Q4 2025, versus $3.8 billion for Q3 2025 and $3.6 billion for Q2 2025.